Aptevo Therapeutics Inc.

25.32-0.5400-2.09%Vol 24.88K1Y Perf 609.86%
Apr 16th, 2021 16:00 DELAYED
BID25.22 ASK25.91
Open26.00 Previous Close25.86
Pre-Market- After-Market-
 - -  - -%
Target Price
65.67 
Analyst Rating
Strong Buy 1.00
Potential %
159.36 
Finscreener Ranking
★+     45.43
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+     38.16
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     33.67
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap112.65M 
Earnings Rating
Neutral
Price Range Ratio 52W %
38.45 
Earnings Date
12th May 2021

Today's Price Range

24.0026.70

52W Range

3.6660.00

5 Year PE Ratio Range

-0.600022.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.29%
1 Month
-31.88%
3 Months
-22.12%
6 Months
262.75%
1 Year
609.86%
3 Years
487.47%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APVO25.32-0.5400-2.09
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.30
0.57
1.65
-
Leverage Ratio 2.80
ProfitabilityValueIndustryS&P 500US Markets
82.60
-88.00
-83.40
-573.50
-68.62
RevenueValueIndustryS&P 500US Markets
4.31M
0.97
-38.06
-25.32
Earnings HistoryEstimateReportedSurprise %
Q03 2020-2.05-2.15-4.88
Q02 2020-2.27-2.107.49
Q01 2020-2.55-2.425.10
Q03 2019-3.36-3.224.17
Q02 2019-5.32-4.2021.05
Q01 2019-6.72-6.168.33
Q03 2018-8.26-7.845.08
Q02 2018-0.65-0.5810.77
Earnings Per EndEstimateRevision %Trend
12/2020 FY-8.780.00-
3/2021 QR-1.624.71Positive
6/2021 QR-1.86-2.20Negative
12/2021 FY-7.20-22.03Negative
Next Report Date12th May 2021
Estimated EPS Next Report-1.62
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume24.88K
Shares Outstanding4.45M
Trades Count447
Dollar Volume6.26M
Avg. Volume59.47K
Avg. Weekly Volume24.52K
Avg. Monthly Volume36.97K
Avg. Quarterly Volume57.75K

Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 25.32 per share at the end of the most recent trading day (a -2.09% change compared to the prior day closing price) with a volume of 24.88K shares and market capitalization of 112.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.

The one-year performance of Aptevo Therapeutics Inc. stock is 609.86%, while year-to-date (YTD) performance is -30.91%. APVO stock has a five-year performance of %. Its 52-week range is between 3.66 and 60, which gives APVO stock a 52-week price range ratio of 38.45%

Aptevo Therapeutics Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 7.15, a price-to-sale (PS) ratio of 25.38, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.78%, a ROC of -70.82% and a ROE of -120.39%. The company’s profit margin is -68.62%, its EBITDA margin is -83.40%, and its revenue ttm is $4.31 Million , which makes it $0.97 revenue per share.

Of the last four earnings reports from Aptevo Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.62 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $65.67, which is +159.36% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.54, ATR14 : 2.83, CCI20 : -76.33, Chaikin Money Flow : -0.36, MACD : -2.60, Money Flow Index : 37.72, ROC : -10.21, RSI : 43.12, STOCH (14,3) : 22.46, STOCH RSI : 0.72, UO : 47.58, Williams %R : -77.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.

CEO: Marvin L. White

Telephone: +1 206 838-0500

Address: 2401 4th Avenue, Seattle 98121, WA, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

62%38%

Bearish Bullish

51%49%

News

Stocktwits